BN
BNTX.US BioNTech SE
- Market cap
- USD 21.2B
- P/E
- -
- P/B
- 1.07x
- ROE
- -8.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BNTX.US undervalued?
Graham numberThe Graham number of BioNTech SE cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioNTech SE fundamental analysis
No fundamental analysis for BioNTech SE yet.
BioNTech SE stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast ca…
Full company profileBioNTech SE financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioNTech SE annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 61.6M | 128M | 109M | 482M | 19.0B | 17.3B | 3.82B | 2.75B | 2.76B | 2.02B |
| Gross Profit | 52.3M | 114M | 91.2M | 423M | 16.1B | 14.3B | 3.22B | 2.21B | 2.14B | 1.49B |
| Operating Income | -61.3M | -53.9M | -182M | -82.4M | 15.3B | 12.6B | 690M | -1.31B | -624M | -1.99B |
| EBITDA | -74.7M | -24.0M | -144M | -105M | 15.0B | 13.1B | 1.38B | -367M | -628M | -630M |
| Net Income | -85.7M | -48.0M | -179M | 15.2M | 10.3B | 9.43B | 930M | -665M | -1.09B | -1.57B |
| EPS | -0.38 | -0.21 | -0.85 | 0.06 | 40 | 38 | 3.83 | -2.77 | -4.51 | -6.20 |
| Balance Sheet | ||||||||||
| Total Assets | 375M | 653M | 798M | 2.32B | 15.8B | 23.3B | 23.0B | 22.5B | 22.0B | 20.2B |
| Total Liabilities | 423M | 386M | 304M | 947M | 3.94B | 3.22B | 2.76B | 3.12B | 2.76B | 2.46B |
| Shareholders' Equity | -49.3M | 266M | 493M | 1.37B | 11.9B | 20.1B | 20.2B | 19.4B | 19.2B | 17.7B |
| Cash & Short-term Investments | 172M | 412M | 521M | 1.35B | 2.07B | 14.1B | 16.5B | 16.8B | 14.8B | 10.2B |
| Total Debt | 50.3M | 54.2M | 76.5M | 240M | 302M | 212M | 219M | 254M | 267M | 360M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -52.6M | -58.2M | -199M | -13.5M | 890M | 13.6B | 5.37B | 208M | 438M | -729M |
| Capital Expenditure | 57.7M | 67.9M | 71.1M | 85.4M | 154M | 363M | 706M | 452M | 168M | 196M |
| Free Cash Flow | -110M | -126M | -270M | -98.9M | 736M | 13.2B | 4.67B | -245M | 270M | -925M |
| Ratios | ||||||||||
| ROE | - | -18.0% | -36.3% | 1.1% | 86.5% | 47.0% | 4.6% | -3.4% | -5.7% | -8.9% |
| ROA | -22.9% | -7.4% | -22.5% | 0.7% | 65.0% | 40.5% | 4.0% | -3.0% | -5.0% | -7.8% |
| Net Profit Margin | -139.1% | -37.6% | -164.9% | 3.2% | 54.2% | 54.5% | 24.4% | -24.2% | -39.6% | -77.7% |
| Debt to Equity | - | 0.20x | 0.16x | 0.18x | 0.03x | 0.01x | 0.01x | 0.01x | 0.01x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BioNTech SE dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 2, 2022
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | EUR 484M | 1.94 | 5.1% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns BioNTech SE
- Insiders 57.86%
- Institutions 20.70%
- Public & others 21.44%
- Shares outstanding 248M
- Free float 106M
Top funds holding BNTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Contrafund | 4.21M | 1.70% | +9.43% | Sep 2026 |
| Dodge & Cox International Stock I | 2.52M | 1.02% | 0.00% | Sep 2026 |
| Vanguard Capital Opportunity Inv | 2.19M | 0.88% | 0.00% | Sep 2026 |
| FvS SICAV Multiple Opportunities F | 1.25M | 0.50% | -12.38% | Jul 2026 |
| First Trust NYSE Arca Biotech ETF | 1.01M | 0.41% | 0.00% | Oct 2026 |
| Fidelity Contrafund K6 | 898K | 0.36% | +9.38% | Sep 2026 |
| PRIMECAP Odyssey Aggressive Growth | 894K | 0.36% | -0.56% | Sep 2026 |
| Fidelity Emerging Markets | 766K | 0.31% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 746K | 0.30% | -0.19% | Oct 2026 |
| T. Rowe Price Mid-Cap Growth | 628K | 0.25% | -18.95% | Sep 2026 |
| Dodge & Cox Global Stock I | 526K | 0.21% | 0.00% | Sep 2026 |
| MFS Mid Cap Value A | 487K | 0.20% | -0.80% | Sep 2026 |
| FvS Multiple Opportunities II I | 470K | 0.19% | -8.73% | Jul 2026 |
| Candriam Eqs L Biotech C USD Cap | 355K | 0.14% | +14.25% | Apr 2026 |
| PRIMECAP Odyssey Growth | 354K | 0.14% | -0.14% | Sep 2026 |
| Dodge & Cox Worldwide Global Stk USD Acc | 349K | 0.14% | +3.56% | Sep 2026 |
| Amundi Fds Global Equity A EUR C | 348K | 0.14% | +1.26% | Sep 2026 |
| Échiquier World Equity Growth A | 345K | 0.14% | 0.00% | Jun 2026 |
| ACATIS Datini Valueflex Fonds A | 339K | 0.14% | 0.00% | Sep 2026 |
| ProfitlichSchmidlin Fonds UI I | 330K | 0.13% | -11.59% | Aug 2026 |
Top institutions holding BNTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 7.57M | 3.05% | +32.62% | Jun 2026 |
| PRIMECAP Management Company | 3.77M | 1.52% | -0.57% | Jun 2026 |
| Dodge & Cox | 3.68M | 1.48% | +0.02% | Jun 2026 |
| Flossbach von Storch AG | 2.23M | 0.90% | -39.51% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 2.07M | 0.83% | -64.73% | Jun 2026 |
| BlackRock Inc | 1.85M | 0.75% | +11.87% | Jun 2026 |
| Temasek Holdings Ltd. | 1.51M | 0.61% | 0.00% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 1.32M | 0.53% | -20.12% | Jun 2026 |
| Logos Global Management LP | 1.02M | 0.41% | 0.00% | Jun 2026 |
| GSK PLC | 890K | 0.36% | 0.00% | Jun 2026 |
| Assenagon Asset Management SA | 847K | 0.34% | 0.00% | Jun 2026 |
| First Trust Advisors L.P. | 791K | 0.32% | -5.78% | Jun 2026 |
| Davern Capital Partners, L.P. | 755K | 0.30% | +147.35% | Jun 2026 |
| UBS Asset Mgmt Americas Inc | 744K | 0.30% | -5.08% | Jun 2026 |
| Massachusetts Financial Services Company | 678K | 0.27% | +1.07% | Jun 2026 |
| Long Focus Capital Management, LLC | 624K | 0.25% | 0.00% | Jun 2026 |
| Baillie Gifford & Co Limited. | 592K | 0.24% | -32.88% | Jun 2026 |
| The Goldman Sachs Group Inc | 590K | 0.24% | +509.22% | Jun 2026 |
| Victory Capital Management Inc. | 540K | 0.22% | +13.18% | Jun 2026 |
| Franklin Templeton Inc | 540K | 0.22% | +40.29% | Jun 2026 |
BioNTech SE company profile
- Company name
- BioNTech SE
- Ticker
- BNTX.US
- Exchange
- USA Stocks
- Listed since
- Oct 10, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7,807
- Fiscal year end
- December
- Address
- An der Goldgrube 12, Mainz, Germany, 55131
- Phone
- 49 6131 9084
- Website
- biontech.de
About BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
BioNTech SE management
10- Dr. Ugur Sahin M.D.Co-Founder, CEO & Chair of the Management Board · born 1965
- Dr. Ozlem Tureci M.D.Co-Founder, Chief Medical Officer & Member of Management Board · born 1967
- Mr. Ramon Zapata-GomezCFO & Member of Management Board · born 1974
- Dr. Sierk Pötting Ph.D.MD, COO & Member of Management Board · born 1973
- Dr. James Timothy Patrick Ryan Ph.D.Chief Legal & Business Officer and Member of the Management Board · born 1975
- Ms. Annemarie HanekampChief Commercial Officer & Member of Management Board · born 1980
- Ms. Kylie JimenezChief People Officer & Member of Management Board · born 1976
- Ms. Lisa BirringerSenior Vice President of Global Financial Reporting & Accounting
- Mr. Douglas Maffei Ph.D.Vice President of Strategy & Investor Relations
- Jasmina AlatovicVice President Corporate Communications